GlassScriptPhysician profile
Janine Wright Bullman
NPI 1417443805
$5,465.46
in general payments reported to CMS, 2019-2025
29 companies · $2,393 in 2025
The $2,393 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.20 · 2022: $349 · 2023: $1,275 · 2024: $1,418 · 2025: $2,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661 · Education: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,660.81 |
| Education | $425.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,813.34 | 2021-2025 | |
| Janssen Biotech, INC. | $1,028.52 | 2023-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $579.14 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $273.71 | 2024-2025 | Voquezna |
| Pfizer INC. | $271.05 | 2023-2025 | |
| Gilead Sciences, INC. | $171.71 | 2021-2025 | Livdelzi |
| Celltrion USA INC. | $143.14 | 2023-2024 | Zymfentra, Yuflyma |
| Intercept Pharmaceuticals, INC. | $125.15 | 2023-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $112.10 | 2023-2025 | Eohilia, Entyvio |
| Organon LLC | $111.44 | 2023-2025 | Hadlima |
| Celgene Corporation | $105.21 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $82.81 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $78.28 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $59.99 | 2022-2023 | Dificid |
| Lilly USA, LLC | $54.74 | 2024-2025 | Omvoh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $50.29 | 2023-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $49.96 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $45.03 | 2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.96 | 2023-2024 | Trulance, Xifaxan, Plenvu |
| Aimmune Therapeutics, INC. | $42.69 | 2025 | Vowst, Zenpep |
| Genzyme Corporation | $37.20 | 2023 | |
| Qol Medical, LLC | $36.57 | 2024-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $31.12 | 2025 | Axonics |
| Mallinckrodt Hospital Products INC. | $26.95 | 2025 | Terlivaz |
| Mylan Institutional INC. | $24.83 | 2023 | Hulio |
| Azurity Pharmaceuticals, INC. | $17.86 | 2025 | Sutab |
| Redhill Biopharma INC. | $17.32 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.01 | 2022 | |
| Evoke Pharma, INC. | $15.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janine Bullman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.